GenomeFrontier Therapeutics TW Co., Ltd.
GenomeFrontier Therapeutics TW Co., Ltd.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-06-12 | NCT06703892 | |
| Long-term Study to Evaluate Safety and Persistence of GF-CART01 | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, neoplasm, primary mediastinal large B-cell lymphoma | Enrolling by invitation | Not stated | 2026-06-11 | NCT06985576 |